These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31943623)

  • 1. Rare case of infiltrative cardiomyopathy secondary to scleromyxoedema.
    Khandkar C; Vaidya K; Penglase R; Cai K; Shin JS; Hunyor I; Keech A; McGill N
    Intern Med J; 2020 Jan; 50(1):127-128. PubMed ID: 31943623
    [No Abstract]   [Full Text] [Related]  

  • 2. An unusual presentation of scleromyxedema as inflammatory myopathy.
    Vysakha KV; Poyuran R; Nair SS; Nair M
    Acta Myol; 2019 Mar; 38(1):13-16. PubMed ID: 31309176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema.
    Brunet-Possenti F; Hermine O; Marinho E; Crickx B; Descamps V
    J Am Acad Dermatol; 2013 Aug; 69(2):319-20. PubMed ID: 23866873
    [No Abstract]   [Full Text] [Related]  

  • 4. Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins.
    Wang SS; Chen QY; Xiang LH
    Front Immunol; 2022; 13():1099918. PubMed ID: 36713453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes.
    Bidier M; Zschoche C; Gholam P; Enk AH; Hadaschik EN
    Acta Derm Venereol; 2012 Jul; 92(4):408-9. PubMed ID: 22278389
    [No Abstract]   [Full Text] [Related]  

  • 6. Scleromyxoedema: the importance of physical examination.
    Pipa S; Sá J; Mondragão A; Marinho A
    BMJ Case Rep; 2018 Oct; 2018():. PubMed ID: 30317211
    [No Abstract]   [Full Text] [Related]  

  • 7. Arndt-Gottron scleromyxoedema: successful therapy with intravenous immunoglobulins.
    Gholam P; Hartmann M; Enk A
    Br J Dermatol; 2007 Nov; 157(5):1058-60. PubMed ID: 17854360
    [No Abstract]   [Full Text] [Related]  

  • 8. Scleromyxedema.
    Hummers LK
    Curr Opin Rheumatol; 2014 Nov; 26(6):658-62. PubMed ID: 25215418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature.
    Efthimiou P; Blanco M
    Semin Arthritis Rheum; 2008 Dec; 38(3):188-94. PubMed ID: 18221985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features of scleromyxoedema in an Afro-Caribbean man.
    Ufodiama CE; Tynes G; Unwala R
    BMJ Case Rep; 2019 Jan; 12(1):. PubMed ID: 30665930
    [No Abstract]   [Full Text] [Related]  

  • 11. Dermato-neuro Syndrome after COVID-19 Vaccination in a Patient with Scleromyxoedema Previously Controlled with Bortezomib and Intravenous Immunoglobulins.
    Gallo R; Trave I; Cotzia E; Russo R; Parodi A
    Acta Derm Venereol; 2022 Dec; 102():adv00836. PubMed ID: 36511333
    [No Abstract]   [Full Text] [Related]  

  • 12. Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone.
    Yeung CK; Loong F; Kwong YL
    Br J Haematol; 2012 May; 157(4):411. PubMed ID: 22429092
    [No Abstract]   [Full Text] [Related]  

  • 13. Dermato-neuro syndrome after COVID-19 infection in a patient with scleromyxoedema: Previously successful treatment with intravenous immunoglobulins.
    Li Y; Wang H; Wang A; Zhao G
    J Dermatol; 2024 Jan; 51(1):140-144. PubMed ID: 37830263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin.
    Rey JB; Luria RB
    J Am Acad Dermatol; 2009 Jun; 60(6):1037-41. PubMed ID: 19249127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing scleromyxedema with intravenous immunoglobulin: acute worsening of scleromyxedema with biclonal gammopathy.
    Manousaridis I; Loeser C; Goerdt S; Hassel JC
    Acta Dermatovenerol Alp Pannonica Adriat; 2010 Dec; 19(4):15-9. PubMed ID: 21390475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Scleromyxedema with neurological symptoms: successful treatment with immunoglobulins].
    Manríquez J; Berroeta-Mauriziano D; Andino-Navarrete R; Vera-Kellet C
    Med Clin (Barc); 2015 Jan; 144(1):47-8. PubMed ID: 24656121
    [No Abstract]   [Full Text] [Related]  

  • 17. [Efficacy of intravenous immunoglobulin in the treatment of scleromyxoedema].
    Sillard L; Passeron T; Cardot-Leccia N; Perrin C; Lacour JP; Ortonne JP
    Ann Dermatol Venereol; 2010 Jan; 137(1):48-52. PubMed ID: 20110069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical characteristics, outcome of scleromyxoedema: a retrospective multicentre study].
    Le Moigne M; Mazereeuw-Hautier J; Bonnetblanc JM; Astudillo L; D'Incan M; Bessis D; Thomas L; Debarbieux S; Ammoury A; Lamant L; Paul C
    Ann Dermatol Venereol; 2010 Dec; 137(12):782-8. PubMed ID: 21134580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scleromyxedema.
    Yang Y; Chen H; Zhang W; Sun JF
    Indian J Dermatol Venereol Leprol; 2016; 82(6):738-739. PubMed ID: 26858056
    [No Abstract]   [Full Text] [Related]  

  • 20. Scleromyxoedema with associated peripheral neuropathy: successful treatment with thalidomide.
    Peter LM; Ammoury A; Chiavassa-Gandois H; Lamant L; Paul CF
    Clin Exp Dermatol; 2008 Aug; 33(5):606-10. PubMed ID: 18477005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.